Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -1.85 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
-
$MRNA will be over $400 by the end of 2021
-
Moderna enters supply agreement for COVID-19 vaccine with Taiwan, Colombia. These agreements are for a total of 15M doses.
-
$182.13 or back to the $186, those are the prices we need to cross over, if that happens, then tomorrow is more likely to be a big Green Day. Of course bad or good news will also change the direction.
Either way, Longs have very nice gains in the last 3weeks. So this little pull back to let the bears breath a little, should do nothing to the big gains we recently have.
So, let’s see where we close today. I personally feel that the $182.13 will be easy to cross.
The charts are showing a very nice setup for tomorrow big run or jump. -
There is nothing to worry here. $MRNA is just starting to be well known, and is getting to be known by being the best in what they do. The pipeline is impressive, and now with the billions they just made from the COVID vaccine, they can expand and invest more in research.
The future for Moderna is bright and more big investor like Bill and Melinda will join. Yes, the Gates are in. They obviously know $MRNA is the future of medicine. -
This is just a little of profits taking. The last 3 weeks has gone up more than 80%. The $186 is a very emotional number for the bears. That is when all of them are finally in the red. So it is very understandable they will do whatever they can to not let us cross the $186.
But bulls and longs know what we own. $MRNA earnings will be amazing on February 25th. Before that we are waiting on the FDA to approve the extra 50% more doses per vial. That news is about to come out soon. That will allow $MRNA to sell a lot more doses without any extra effort.
By the way, $MRNA is or was expected to report a loss of $0.21, but we all know that prediction was made before the vaccine was approved and selling. That means $MRNA will report the biggest surprise.
So, hold your stocks longer or buy more before earnings. -
@ Collin
You are a fake propaganda machine. Test tube experiments is not equal to clinical trials. -
NVAX is currently sitting at #2 when it comes to global contracts. Since many countries dropping AZ and Sanofi and that will make NOVAVAX #1.
Follow the link. Moderna is inflated. -
Sanofi 121B company, whereas Moderna is 73B. Moderna is inflated. NOVAVAX is undervalued at 21B. Go do your math.
-
$MRNA the fight of the $185.99 is coming to an end. I can’t believe that Bank of America delayed us a week
-
$MRNA the fight of the $185.99 is coming to and end.
-
Dumb bears will keep shorting here
-
Unless they shorted in the PRE MARKET when it was $210
-
Come on, this fight of the $186 should be done already. The bears are just fighting it for sentimental value, because at that point none of them are in the green anymore.
-
If it wasn’t for the stupid Bank of America so called analysts, $MRNA would be already hitting the $300
-
Bears are fighting hard to keep it below the $186. As soon they give up, we will be heading to the $200 fast. So fast those hedge funds bears won’t even have time to cry. They will just faint.
-
-
The shorts that got in with the horrible guidance from Bank of America are loosing. They should go after Bank of America for misguiding them. Lol.
Just a reminder to old and new shorts. You better have a lot more money, otherwise you will end up like some hedge funds from a week ago crying on national television.
$MRNA is actually making billions, it will report an EPS jump of over 5000% year over year. So the price of the stock has plenty to go up due to their new EPS that will be reported in 2 weeks. -
We will be at $250-$260 before earnings, and after earnings report, we will jump to the $300s. A lot of Investors are waiting for the first report to make sure $MRNA is a real solid investment.
New investors will make good money, but early investors let’s just say, are going to be extra happy. -
As soon the $185.99 is done. The $200 is next.
-
NTx Services Launches to Supercharge Next Generation mRNA Research
businesswire.com • -
Moderna (NASDAQ:MRNA) Shares Up 7%
news.google.com • -
Moderna (NASDAQ:MRNA) PT Lowered to $48.00
news.google.com • -
What's Going On With Moderna Shares Tuesday?
news.google.com • -
Where are the Opportunities in (MRNA)
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein
news.google.com • -
Moderna's Recent Drop: 4 Reasons Bulls See Opportunity
marketbeat.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)
news.google.com • -
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
news.google.com • -
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
news.google.com • -
‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
news.google.com • -
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
news.google.com • -
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts
news.google.com • -
Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline (NASDAQ:MRNA)
news.google.com • -
Moderna: Looking For The Bottom (NASDAQ:MRNA)
news.google.com • -
Moderna stock slides on downgrades tied to profitability delay
news.google.com • -
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
news.google.com • -
Moderna: Oddo BHF reduces its target after CMD
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Big Rate Cut or Small, U.S. Stocks Are Priced for Middling Returns
news.google.com • -
Moderna Stock Hits Lowest Since 2020. What’s Behind the Tumble.
news.google.com • -
Biggest stock movers today: MPW, MRNA, NTGR, and more
news.google.com • -
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
news.google.com • -
Moderna Stock Plummets on Cost-Cutting Measures
news.google.com • -
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
news.google.com • -
Biggest stock movers today: WBD, MPW, MRNA, SIG, and more (NYSE:OXM)
news.google.com • -
Moderna stock plunges after slashing R&D budget
news.google.com • -
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
news.google.com •